论文部分内容阅读
目的观察普罗布考对T2DM合并轻度认知功能障碍(MCI)患者改善的情况。方法根据蒙特利尔认知评估(MoCA)量表北京版结果选取糖尿病合并MCI(MoCA<26分)患者88例,随机分为治疗组46例与对照组42例。干预6个月,比较治疗前后两组MoCA评分、β淀粉样蛋白40(Aβ1-40)和颈动脉内-中膜厚度(CIMT)的差异。结果两组完成随访人数分别为42例和40例。治疗后,治疗组Aβ1-40较对照组降低[135.05(35.32,221.23)vs 174.15(85.13,327.77)pg/ml,P<0.01],两组MoCA评分比较,差异无统计学意义(P>0.05)。两组治疗前后临床参数自身差值(Δ=治疗前-治疗后)比较,差异均有统计学意义[ΔMoCA:-4.00(-5.00,-2.00)vs-1.00(-3.00,0.00),P<0.01;ΔAβ1-40:68.61(-58.59,198.76)vs 9.00(-110.65,106.67)pg/ml,P=0.02;ΔCIMT:0.05(-0.05,0.20)vs-0.05(-0.10,0.10)mm,P=0.02]。结论普罗布考可降低T2DM合并MCI患者Aβ1-40水平,改善认知功能。
Objective To observe the improvement of probucol in T2DM patients with mild cognitive impairment (MCI). Methods Eighty-eight patients with diabetes mellitus and MCI (MoCA <26 points) were selected according to the results of the Beijing version of the Montreal Cognitive Assessment (MoCA) Scale. They were randomly divided into treatment group (46 cases) and control group (42 cases). After intervention for 6 months, the differences of MoCA score, amyloid beta 40 (Aβ1-40) and carotid artery intima-media thickness (CIMT) between the two groups were compared before and after treatment. Results The number of follow-up in both groups was 42 and 40 respectively. After treatment, the Aβ1-40 in the treatment group was lower than that in the control group [135.05 (35.32,221.23) vs 174.15 (85.13,327.77) pg / ml, P <0.01]. There was no significant difference in MoCA score between the two groups ). The difference between the two groups was statistically significant (ΔMoCA: -4.00 (-5.00, -2.00) vs-1.00 (-3.00,0.00), P < 0.01; ΔAβ1-40: 68.61 (-58.59, 198.76) vs 9.00 (-110.65, 106.67) pg / ml, P = 0.02; ΔCIMT: 0.05 (-0.05,0.20) vs-0.05 = 0.02]. Conclusion Probucol can reduce Aβ1-40 levels in T2DM patients with MCI and improve cognitive function.